- Home
- ATTO vs DSGN Comparison
ATTO vs DSGN Comparison
Compare ATTO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATTO | DSGN |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 853.8M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATTO | DSGN |
|---|---|---|
| Price | $15.96 | $10.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $42.20 | $21.57 |
| AVG Volume (30 Days) | 324.6K | ★ 416.0K |
| Earning Date | 09-02-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.94 | $6.81 |
| 52 Week High | $28.00 | $17.25 |
Technical Indicators
Market Signals| Indicator | ATTO | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 47.71 |
| Support Level | $12.94 | $9.83 |
| Resistance Level | $16.83 | $11.43 |
| Average True Range (ATR) | 1.32 | 0.61 |
| MACD | 0.33 | 0.08 |
| Stochastic Oscillator | 73.64 | 60.94 |
Price Performance
Historical ComparisonAbout ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.